Clinical Trial Update: Fasenra Pediatric Japan Post-Marketing Study(PMS)

View source ↗

Summary

AstraZeneca is conducting a pediatric post-marketing study of benralizumab (Fasenra) in Japan for bronchial asthma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Asthma

Drugs mentioned

• FASENRA (BENRALIZUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Bronchial Asthma | Status: RECRUITING